Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises 1Vision Biogas on its public offer for Biokraft
Mandate

Vinge advises 1Vision Biogas on its public offer for Biokraft

February 05, 2024 Capital Markets and Public M&A M&A FDI EU, Competition and Regulatory

1Vision Biogas AB, a company controlled by Aneo, HitecVision and St1, has made a public mandatory bid for all shares in Biokraft International AB. The offer values the shares of Biokraft at approximately SEK 900 million. Vinge advises 1Vision Biogas.

The Vinge team includes Christian Lindhé, Erik Sjöman, Martin Madsen Svanberg, Johan Åhman and Johan Severinsson (Capital Markets and Public M&A), Jesper Ottergren (M&A) as well as Sofie Nordgren, Pär Remnelid, Rikard Azelius and Jasmine Elgh (FDI/EU, Competition and Regulatory).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025